«
»

Top

Cleveland Researchers Develop A New Treatment for Multiple Sclerosis And Launch a Company to Test It

Jul 27, 2018 • 2 comments

Cleveland Researchers Develop A New Treatment for Multiple Sclerosis And Launch a Company to Test It

A team at Case Western Reserve University has come up with a new approach to treating Multiple Sclerosis.

They have also launched a business to bring the new therapy to market.

The company is called Convelo Therapeutics.

Co-founders Paul Tesar and Drew Adams collaborated on research at Case Western Reserve University School of Medicine that focused on restoring the brain cells that produce the protective coating on nerve cells called myelin.

In MS the myelin is stripped away, leading to loss of movement and other impairments for those affected.

Tesar and Adams discovered a set of molecules that allow cells in the brain called oligodendrocytes to repair the damage.

Tesar hopes the new company can bring the drugs from the lab to the bedside.

“Something that Drew and I felt very strongly about was to get this out into the commercial sector into an early-stage company that could develop and discover these and

Investors provided $7.8 million in seed capital to begin the work of testing in humans.

Tesar said the company will also begin development of therapies for brain injuries and Alzheimer’s using the new technology.

MS affects 2.3 million people worldwide.

WKSU

Comments

LynndMS
on 7/30/18

Wow!! This would be a Godsend. I wonder if there are trials or what the cost is ... thank you for posting!!’ 

suplkr1
on 8/1/18

I looked into it... here is the company's website https://www.convelotx.com/news/

You will also like

Expert Interview: Understanding neuropsychology (3/3)

Alzheimer's disease

Expert Interview: Understanding neuropsychology (3/3)

Read the article
Castleman Disease: Everything you need to know!

Castleman disease

Castleman Disease: Everything you need to know!

Read the article
Melanoma: How do you know if a mole is dangerous?

Melanoma: How do you know if a mole is dangerous?

Read the article
Meet Marie-Gabrielle, our Product & Engagement Manager

Meet Marie-Gabrielle, our Product & Engagement Manager

Read the article